Shortened antituberculosis treatment regimens are expected to improve patient adherence to treatment, thus favoring better case management and disease control and minimizing the risk of drug resistance.1-3 The first indication that fluoroquinolones had the potential to shorten tuberculosis treatment was from an observational study in India4 in which ethambutol was replaced with ofloxacin.